Alpha Tau Medical Ltd

Alpha Tau Medical’s 2026 ASCO data show a 42 % objective response and 65 % 12‑month survival for pancreatic cancer using its alpha‑emitter platform, promising a breakthrough in solid‑tumor therapy.

Alpha Tau Medical Ltd is a leading developer of innovative radiation therapy solutions for solid tumors, offering a targeted approach to cancer treatment and serving a global patient base.

Alpha Tau Medical Ltd. reported a GAAP EPS of -$0.11 for Q1 2025, but remains focused on advancing its cancer treatment technologies and expanding its market presence.